This inventor holds 7 USPTO granted patents and 11 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignees: Tilt Biotherapeutics Oy, Targovax Oy. Active years: 2016-2026.
Company Filing History:
Years Active: 2016-2026
Title: Akseli Hemminki: Innovator in Cancer Therapies
Introduction
Akseli Hemminki is a prominent inventor based in Helsinki, Finland. He has made significant contributions to the field of cancer therapies, particularly through his innovative work with oncolytic adenoviral vectors. With a total of 7 patents to his name, Hemminki is recognized for his advancements in adoptive cell therapy and related therapeutic methods.
Latest Patents
Hemminki's latest patents include groundbreaking inventions in the realm of cancer treatment. One notable patent focuses on enhanced adoptive cell therapy, which discloses oncolytic adenoviral vectors used alone or in combination with therapeutic compositions for cancer treatment. This patent also details the separate administration of adoptive cell therapeutic compositions alongside oncolytic adenoviral vectors. Another significant patent involves oncolytic adenoviruses that code for bi-specific antibodies, which are crucial for developing effective cancer therapies in humans. This invention encompasses methods and uses of oncolytic adenoviral vectors, often in conjunction with adoptive cell therapies.
Career Highlights
Throughout his career, Akseli Hemminki has worked with notable companies in the biotechnology sector, including Tilt Biotherapeutics and Targovax. His work in these organizations has furthered the development of innovative cancer therapies, showcasing his commitment to improving patient outcomes.
Collaborations
Hemminki has collaborated with esteemed colleagues in the field, including Vincenzo Cerullo and Siri Tähtinen. These partnerships have contributed to the advancement of his research and the successful implementation of his inventions.
Conclusion
Akseli Hemminki stands out as a leading inventor in the field of cancer therapies, with a focus on oncolytic adenoviral vectors and adoptive cell therapy. His contributions are paving the way for new treatment options that could significantly impact cancer care.